ArticleDiagnostic pathology2012
Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma.
Article in Diagnostic pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Changes in the Extracellular Matrix in Endometrial and Cervical Cancer: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Cruciferous vegetables consumption and the risk of ovarian cancer: a meta-analysis of observational studies.Diagnostic pathology · 2014Pooled it
- Update on the Association of CD44 Expression with Esophageal Squamous Cell Carcinoma Invasion.Reports of biochemistry & molecular biology · 2025Article
- Fascin-1: Updated biological functions and therapeutic implications in cancer biology.BBA advances · 2022Review
- FSCN1 acts as a promising therapeutic target in the blockade of tumor cell motility: a review of its function, mechanism, and clinical significance.Journal of Cancer · 2022Review
- Review
- Fascin actin-bundling protein 1 in human cancer: promising biomarker or therapeutic target?Molecular therapy oncolytics · 2021Review
- Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer.Pathology oncology research : POR · 2019Article
- The meta and bioinformatics analysis of fascin expression in gastric cancer: a potential marker for aggressiveness and worse prognosis.Oncotarget · 2017Article
- Article
- Over-expression of Sox4 and β-catenin is associated with a less favorable prognosis of osteosarcoma.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2016Article
- Swiprosin-1 stimulates cancer invasion and metastasis by increasing the Rho family of GTPase signaling.Oncotarget · 2015Article
- CD44 expression in curettage and postoperative specimens of endometrial cancer.Archives of gynecology and obstetrics · 2015Article
- Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer.BioMed research international · 2015Article
- Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.Diagnostic pathology · 2014Article
- CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms.Diagnostic pathology · 2013Article
- CD44v6 expression in human skin keratinocytes as a possible mechanism for carcinogenesis associated with chronic arsenic exposure.European journal of histochemistry : EJH · 2013Article
- Knockdown of TRPM8 suppresses cancer malignancy and enhances epirubicin-induced apoptosis in human osteosarcoma cells.International journal of biological sciences · 2013Article
- The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma.BioMed research international · 2013Article
- Actin binding proteins: their ups and downs in metastatic life.Cell adhesion & migrationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFascin and CD44v6 may have significant roles as biomarkers in tumour progression and metastasis. In endometrioid carcinomas, the fascin expression profile is less defined, and the significance of CD44v6 is uncertain. We aimed to investigate the expressions of both fascin and CD44v6 in endometrioid carcinomas and to evaluate their inter-relation with clinicopathological parameters.
methodsFascin and CD44v6 expressions were evaluated, individually and in combination, in a series of 47 endometrioid carcinomas and 10 proliferative endometrium samples. The staining extent and intensity of both markers in tumour cells were scored semiquantitatively. The relationship between immunoexpressions and clinicopathological variables was assessed.
resultsThe expression rates of fascin and CD44v6 in endometrioid carcinoma were 72.34% and 46.80%, respectively. Although these expression rates were higher than those in proliferative endometrial samples, fascin expression showed a statistically significant difference from the normal group (p = 0.02), but CD44v6 did not differ (p = 0.54). Fascin expression was significantly correlated with tumour grade (p = 0.003) and neural invasion (p = 0.036) in a univariate analysis. In contrast, no significant correlation was found between CD44v6 and any of the clinicopathological parameters.
conclusionsOur findings suggest that fascin might be an independent prognostic indicator in the different steps of extracellular matrix invasion. On the other hand, CD44v6 was not a predictive factor in endometrioid cancer. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8511594927206899.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.